Hongwei Lü
- Cancer Research top 5%
- Cancer-related molecular mechanisms research 10
- MicroRNA in disease regulation 6
- Hepatology top 10%
- Liver Disease and Transplantation 8
- Molecular Biology top 10%
- Sphingolipid Metabolism and Signaling 10
- RNA modifications and cancer 9
- Cell Biology top 10%
- Rheumatology top 10%
-
- Organ Transplantation Techniques and Outcomes 7
-
- Liver Disease Diagnosis and Treatment 7
-
- Immune cells in cancer 7
- Journals
- Advanced Materials (1 paper)Journal of Biological Chemistry (1 paper)Journal of Neuroscience (1 paper)
- Partner nations
- ChinaUnited StatesAustralia
In The Last Decade
Hongwei Lü
99 papers receiving 1.6k citations
Peers
Comparison fields: 5 of 120
- Cancer Research 311
- Hepatology 110
- Molecular Biology 814
- Cell Biology 131
- Rheumatology 115
Countries citing papers authored by Hongwei Lü
This map shows the geographic impact of Hongwei Lü's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hongwei Lü with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hongwei Lü more than expected).
Fields of papers citing papers by Hongwei Lü
This network shows the impact of papers produced by Hongwei Lü. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hongwei Lü. The network helps show where Hongwei Lü may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Hongwei Lü, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 40 | |
| 4 | 2024 | 10 | |
| 5 | 2024 | 1 | |
| 6 | 2024 | 1 | |
| 7 | 2024 | 0 | |
| 8 | 2024 | 4 | |
| 9 | 2023 | 1 | |
| 10 | 2023 | 4 | |
| 11 | 2023 | 10 | |
| 12 | 2023 | 6 | |
| 13 | 2022 | 7 | |
| 14 | 2022 | 45 | |
| 15 | 2022 | 7 | |
| 16 | 2021 | 9 | |
| 17 | 2020 | 16 | |
| 18 | 2020 | 25 | |
| 19 | 2016 | 8 | |
| 20 | 2014 | 62 |
About Hongwei Lü
Hongwei Lü is a scholar working on Hepatology, Cancer Research and Nephrology, having authored 106 papers that have together received 1.7k indexed citations. Recurring topics across this work include Sphingolipid Metabolism and Signaling (10 papers), Cancer-related molecular mechanisms research (10 papers), RNA modifications and cancer (9 papers), Liver Disease and Transplantation (8 papers), Organ Transplantation Techniques and Outcomes (7 papers), Liver Disease Diagnosis and Treatment (7 papers), Immune cells in cancer (7 papers) and MicroRNA in disease regulation (6 papers). The work is most often cited by research in Cancer Research (311 citations), Hepatology (110 citations) and Molecular Biology (814 citations). Hongwei Lü has collaborated with scholars based in China, United States and Australia. Frequent co-authors include Hong Ji, Hong Xiang, Shuhua Chen, Le Lü, Yiming Li, Yafei Zhang, Xianling Zeng, Meng Fan, Lin Zeng and Jingjing Huang. Their work appears in journals such as Advanced Materials, Journal of Biological Chemistry and Journal of Neuroscience.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.